Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup

Citigroup began coverage on Kiniksa Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $40.00 target price for the company.